AIM ImmunoTech Rights Offering Results

AIM ImmunoTech Inc., an immuno-pharma company, announced the preliminary results of its rights offering, which expired on March 3, 2026. The offering is estimated to have raised approximately $1.8 million. The terms of the offering allowed holders to purchase units, each consisting of one share of Series G Convertible Preferred Stock and 2,000 Class G Common Stock Purchase Warrants, at a subscription price of $1,000 per unit. The Preferred Stock is convertible into 1,000 shares of Common Stock, and the Warrants are exercisable for one share of Common Stock at $1.00 per share for five years. Maxim Group LLC acted as the dealer-manager, and Broadridge Corporate Issuer Solutions, LLC served as the subscription agent. The United States===United States Securities and Exchange Commission declared the registration statement effective on February 10, 2026. The capital raised will support AIM ImmunoTech's focus on developing Ampligen for late-stage pancreatic cancer.